title: Cardiovascular prevention in the cancer survivor.
abstract: Cancer survivorship should be defined starting not from completion of treatment, but from the time of diagnosis. Assessing and controlling the cancer patient's cardiovascular risk before, during, and after treatment is crucial to improving their overall outcome. There are many cancer therapies, including but not limited to anthracyclines, radiation, and vascular signaling pathway inhibitors which should be considered nontraditional cardiovascular risk factors with significant morbidity. Monitoring novel populations, such as a younger age group, for ischemic coronary disease or congestive heart failure (CHF) is not intuitive to many clinicians. Symptoms of CHF and coronary artery disease overlap with common side effects of cancer and cancer treatment. Cancer survivors may also have fewer typical symptoms of cardiovascular disease. Increased surveillance and aggressive control of cardiovascular disease is important in cancer patients both while undergoing active treatment and in the long term. Despite the increasing interest in cardio-oncology, data-driven guidelines are lacking due to small study sizes and low event rates over a short period of time. Most practice guidelines have been based on clinical practice and expert opinion. The list of cardiotoxic cancer therapies continues to grow each year. This review is not intended to be a comprehensive review of all cancer therapy toxicity, but will focus on recent literature regarding prevention of CHF and coronary artery disease (CAD) during active cancer therapy as well as current screening guidelines for long-term survivors.
authors: Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 260, New York, NY, 10065, USA, chenc@mskcc.org.
authors: Carol L
authors: CL
authors: Chen
mesh_terms: D000818:Animals; D066126:Cardiotoxicity / Q000517:prevention & control*; D002319:Cardiovascular System / Q000503:physiopathology; D003327:Coronary Disease / Q000517:prevention & control*; D006801:Humans; D017202:Myocardial Ischemia / Q000517:prevention & control*; D009369:Neoplasms / Q000401:mortality*; D017741:Survivors
references: Cancer. 2014 May 1;120(9):1290-314
references: 24343171
references: Circulation. 2006 Dec 5;114(23):2474-81
references: 17101852
references: J Clin Oncol. 2012 Oct 20;30(30):3752-63
references: 23008318
references: Clin Cancer Res. 2011 May 15;17(10):3490-9
references: 21372222
references: J Clin Oncol. 2012 Nov 1;30(31):3792-9
references: 22987084
references: J Clin Oncol. 2002 Dec 1;20(23):4517-22
references: 12454107
references: J Clin Oncol. 2012 May 1;30(13):1415-21
references: 22124095
references: J Clin Oncol. 2012 May 1;30(13):1422-8
references: 21900104
references: Lancet. 2007 Dec 15;370(9604):2011-9
references: 18083403
references: N Engl J Med. 2011 Oct 6;365(14):1273-83
references: 21991949
references: Ann Oncol. 2012 Dec;23 (12 ):3180-7
references: 22858558
references: J Clin Oncol. 2006 Jan 20;24(3):467-75
references: 16421423
references: Eur Heart J Cardiovasc Imaging. 2014 Mar;15(3):324-31
references: 24057661
references: J Am Coll Cardiol. 2012 Dec 18;60(24):2504-12
references: 23158536
references: Breast Cancer Res Treat. 2013 Aug;140(3):453-62
references: 23907751
references: J Clin Oncol. 2014 Jul 10;32(20):2159-65
references: 24912899
references: Circulation. 2010 Feb 16;121(6):833-40
references: 20124128
references: J Clin Oncol. 2009 Jan 1;27(1):127-45
references: 19018081
references: J Natl Compr Canc Netw. 2012 Apr;10(4):537-44
references: 22491050
references: N Engl J Med. 2007 Jan 11;356(2):125-34
references: 17215530
references: Invest New Drugs. 2014 Aug;32(4):717-22
references: 24764123
references: Eur J Cancer. 2011 Jun;47(9):1287-98
references: 21481584
references: Circ Cardiovasc Imaging. 2012 Sep 1;5(5):596-603
references: 22744937
references: J Clin Oncol. 2014 Mar 1;32(7):647-53
references: 24470002
references: JAMA. 1991 Sep 25;266(12 ):1672-7
references: 1886191
references: Br J Radiol. 2013 Feb;86(1022):20120434
references: 23385997
references: J Natl Cancer Inst. 2011 May 4;103(9):763-73
references: 21527770
references: Br J Cancer. 2014 Feb 18;110(4):829-30
references: 24548883
references: J Clin Oncol. 2001 Jul 1;19(13):3163-72
references: 11432882
references: Cancer. 2014 Sep 1;120(17):2742-50
references: 25070001
references: J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239
references: 23747642
references: Acta Oncol. 2014 Jan;53(1):65-74
references: 23957716
references: J Clin Oncol. 2012 Jul 10;30(20):2530-7
references: 22614980
references: Cancer. 2007 Oct 1;110(7):1493-500
references: 17657815
references: Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):980-7
references: 19251085
references: J Am Coll Cardiol. 2010 Jan 19;55(3):213-20
references: 20117401
references: Lancet Oncol. 2010 Oct;11(10 ):950-61
references: 20850381
references: N Engl J Med. 2006 Oct 12;355(15):1572-82
references: 17035650
references: Int J Cancer. 2015 Apr 1;136(7):1655-64
references: 25110999
references: J Natl Cancer Inst. 2007 Feb 7;99(3):206-14
references: 17284715
references: JAMA. 2003 Dec 3;290(21):2831-7
references: 14657067
references: Am J Cardiol. 2007 Feb 15;99(4):535-40
references: 17293199
references: J Am Heart Assoc. 2014 Feb 28;3(1):e000472
references: 24584736
references: Br J Cancer. 2013 Jul 9;109(1):60-7
references: 23660945
references: Eur J Cancer. 2013 Sep;49(13):2900-9
references: 23706982
references: Breast Cancer Res Treat. 2014 Jul;146(2):411-9
references: 24951268
references: J Clin Oncol. 2010 Sep 1;28(25):3910-6
references: 20679614
references: J Am Coll Cardiol. 2014 Mar 4;63(8):809-16
references: 24291281
references: Cancer. 2010 Oct 15;116(20):4825-32
references: 20597134
references: Breast Cancer Res Treat. 2012 Feb;131(3):907-14
references: 22042368
references: Semin Oncol. 2013 Dec;40(6):690-708
references: 24331191
references: J Card Fail. 2014 Mar;20(3):155-8
references: 24378722
references: J Clin Oncol. 2000 Apr;18(8):1725-32
references: 10764433
references: J Clin Oncol. 2007 Jan 1;25(1):43-9
references: 17194904
references: Ann Oncol. 2009 Sep;20(9):1535-42
references: 19474115
references: Lancet. 2008 Aug 9;372(9637):449-56
references: 18653228
references: CA Cancer J Clin. 2014 Jul-Aug;64(4):252-71
references: 24890451
references: J Am Soc Echocardiogr. 2014 Sep;27(9):911-39
references: 25172399
references: Eur Heart J. 2000 Jan;21(2):154-61
references: 10637089
references: N Engl J Med. 2001 Mar 15;344(11):783-92
references: 11248153
references: J Clin Oncol. 2005 Aug 20;23(24):5814-30
references: 16043830
references: Ann Intern Med. 2014 May 20;160(10 ):672-83
references: 24842414
references: BMJ Open. 2013 Nov 04;3(11):e003556
references: 24189081
references: Circulation. 2004 Jun 8;109(22):2749-54
references: 15148277
references: J Clin Oncol. 2008 Nov 10;26(32):5204-12
references: 18838713
references: Ann Intern Med. 2014 May 20;160(10 ):661-71
references: 24842413
references: Eur J Cancer. 2011 Jun;47(9):1373-9
references: 21514146
references: J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2751-68
references: 24703918
references: J Natl Compr Canc Netw. 2013 Jan 1;11(1):5-9
references: 23307976
references: J Clin Oncol. 2007 Jul 20;25(21):3031-7
references: 17634481
references: J Am Soc Echocardiogr. 2013 May;26(5):493-8
references: 23562088
references: Cancer Treat Rev. 2011 Aug;37(5):391-403
references: 21333452
references: Int J Cancer. 2014 Feb 1;134(3):664-73
references: 23852751
references: Circulation. 2013 Oct 22;128(17):1927-95
references: 24081971
references: Med Sci Sports Exerc. 2010 Jul;42(7):1409-26
references: 20559064
references: Cancer. 2013 Oct 1;119(19):3555-62
references: 23861158
references: Circulation. 2002 Aug 6;106(6):666-71
references: 12163425
references: J Am Coll Cardiol. 2011 Mar 1;57(9):1126-66
references: 21349406
references: Ann Oncol. 2013 Mar;24(3):749-55
references: 23131388
references: J Clin Oncol. 2008 Mar 10;26(8):1231-8
references: 18250349
references: J Clin Oncol. 2013 Oct 10;31(29):3673-80
references: 24002505
references: N Engl J Med. 2013 Mar 14;368(11):987-98
references: 23484825